Factor X Activator for Hemophilia Patients with Inhibitors: A Phase 1, First-in-Human, Multi-Center, and Open-Label Trial

被引：0
|
作者：
Liu, Wei [1 ,2 ]
Xue, Feng [1 ,2 ]
Fu, Rongfeng [1 ,2 ]
Ding, Bingjie [3 ,4 ]
Li, Mengjuan [1 ,2 ]
Sun, Ting [1 ,2 ]
Chen, Yunfei [1 ,2 ]
Liu Xiaofan [1 ,2 ]
Ju, Mankai [1 ,2 ]
Dai, Xinyue [1 ,2 ]
Wu, Quanrui [5 ]
Zhou, Zan [5 ]
Wang, Xiaomin [5 ]
Yu, Jiaojiao [5 ]
Zhou, Hu [3 ,4 ]
Yang, Renchi [1 ,2 ]
Zhang, Lei [1 ,2 ]
机构：
[1] Chinese Acad Med Sci, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,Inst Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Henan Canc Hosp, Hemostasis & Thrombosis Diagnost Engn Res Ctr Hen, Zhengzhou, Peoples R China
[5] Staidson Beijing Biopharmaceut Co Ltd, Beijing, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159948
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8474 / 8475
页数：2
相关论文
共 50 条
  • [31] A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis
    Verstovsek, Srdan
    Hoffman, Ronald
    Mascarenhas, John
    Soria, Jean-Charles
    Bahleda, Ratislav
    McCoon, Patricia
    Tang, Weifeng
    Cortes, Jorge
    Kantarjian, Hagop
    Ribrag, Vincent
    LEUKEMIA RESEARCH, 2015, 39 (02) : 157 - 163
  • [32] An Ongoing Phase 2, Multi-Center, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients
    Schilsky, Michael L.
    Askari, Frederick K.
    Ferenci, Peter
    Czlonkowska, Anna
    Nicholl, David J.
    Bronstein, Jeffrey
    Bega, Danny
    Weiss, Karl Heinz
    HEPATOLOGY, 2016, 64 : 281A - 282A
  • [33] Magnetic guided localization for non-palpable breast lesion: A multi-center open-label trial in Japan
    Kurita, Tomoko
    Taruno, Kanae
    Nakamura, Seigo
    Takei, Hiroyuki
    Enokido, Katsutoshi
    Kuwayama, Takashi
    Kanada, Yoko
    Akashi, Sadako
    Nakai, Maki
    Hankyo, Meishi
    Yanagihara, Keiko
    Sakatani, Takashi
    Sakamaki, Kentaro
    Kuwahata, Akihiko
    Sekino, Masaki
    Kusakabe, Moriaki
    CANCER RESEARCH, 2020, 80 (04)
  • [34] Effect of a 1-year short message service in detoxified alcohol-dependent patients: a multi-center, open-label randomized controlled trial
    Lucht, Michael
    Quellmalz, Anne
    Mende, Meinhard
    Broda, Anja
    Schmiedeknecht, Anett
    Brosteanu, Oana
    Hoeppner-Buchmann, Jacqueline
    Langosch, Jens
    Stuppe, Markus
    Schomerus, Georg
    Klauer, Thomas
    Grabe, Hans J.
    Freyberger, Harald J.
    John, Ulrich
    Meyer, Christian
    ADDICTION, 2021, 116 (06) : 1431 - 1442
  • [35] Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia a without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)
    Shima, Midori
    Nogami, Keiji
    Nagami, Sayaka
    Yoshida, Seitaro
    Yoneyama, Koichiro
    Ishiguro, Akira
    Suzuki, Takashi
    Taki, Masashi
    BLOOD, 2018, 132
  • [36] A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
    George, Suzanne
    Heinrich, Michael C.
    Somaiah, Neeta
    Oppelt, Peter
    McLeod, Robert
    Nishioka, Satoshi
    Kundu, Madan G.
    Qian, Xiaozhong
    Kumar, Prasanna
    Laadem, Abderrahmane
    Lau, Yvonne
    Tran, Brittany P.
    Fallon, Maura
    Dosunmu, Ololade
    Shi, Julia
    Naito, Yoichi
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3659 - 3667
  • [37] A first-in-human, open-label, phase I trial of daily oral zelenirstat, an NMT inhibitor, in patients with relapsed/refractory advanced cancer including gastrointestinal cancers
    Spratlin, Jennifer L.
    Sangha, Randeep S.
    Jamal, Rahima
    Beauchamp, Erwan
    Berthiaume, Luc G.
    Mackey, John Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 129 - 129
  • [38] Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial
    Sung, H. H.
    Han, D. H.
    Kim, T. H.
    Lee, Y. -S.
    Lee, H. N.
    Seo, J. T.
    Choo, M. -S.
    Lee, K. -S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (11) : 1309 - 1315
  • [39] Memantine Treatment in Patients with Alzheimer's Disease Is Associated with a Slower Right Hippocampal Volume Loss: An Open-Label, Multi-Center Trial
    Weiner, Michael W.
    Graham, Stephen M.
    Holbatter, Robert K.
    Yu, Sung Y.
    Li, Shaoyi
    Hsu, Hai-An
    Suhy, Joyce
    Perhach, James L.
    NEUROLOGY, 2009, 72 (11) : A150 - A150
  • [40] Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial
    Shen, Yuanming
    Kong, Beihua
    Xia, Bairong
    Wang, Fei
    Yin, Rutie
    Li, Qingshui
    Yue, Ying
    Kang, Shan
    He, Liping
    Wang, Ke
    Meng, Yuanguang
    Wang, Shixuan
    Qu, Pengpeng
    Huang, Xianghua
    Guo, Ruixia
    Yan, Ping
    Pan, Mei
    Lou, Ge
    Cheng, Wenjun
    Xie, Xing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345